Close
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) Jun 2, 2024 10:01AM

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, human epidermal growth factor receptor 2-negative (HER2-negative), hormone receptor-positive metastatic breast cancer (TBCRC 041; ... (continue reading...)


MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer Jun 2, 2024 10:00AM
  • The PRIMED study found a way to reduce treatment-related side effects among participants, decreasing dose reductions, treatment interruptions, and permanent discontinuations.
  • The strategic alliance between MEDSIR and Oncoclínicas has enabled the company to present 13 studies at the 2024 ASCO Annual Meeting.

CHICAGO, June 2, 2024 /PRNewswire/ -- Leading international medical research company, MEDSIR, today announced the results of the recent PRIMED clinical trial... (continue reading...)


Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC) Jun 2, 2024 10:00AM

-Trial-in-Progress poster provides overview on PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with recurrent/metastatic HNSCC-

LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 2, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO... (continue reading...)


Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Jun 2, 2024 10:00AM
  • HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancers
  • ER status was accurately assessed and the level of ER pathway activation quantified in 87 patients with advanced breast cancer
  • Results support the relevance of the Precede Bio platform to the more than 70 therapeutics directly targeting HER2 and the ER pathway in active clinical development

BOSTON, June 02, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a... (continue reading...)


ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer Jun 2, 2024 10:00AM
  • Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated
  • Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET

SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an... (continue reading...)


More Press Releases

View Older Stories

Jun 2, 2024 10:00AM Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 The
Jun 2, 2024 09:49AM The Curious Journey of Qurious Media Singapore: Revolutionizing Digital Marketing for Small Businesses
Jun 2, 2024 09:49AM GTS Nordic Expands with North Carolina Office to Meet Rising Demand for Compliant Employment Solutions in the United States
Jun 2, 2024 09:51AM BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jun 2, 2024 09:43AM Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
Jun 2, 2024 09:30AM Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
Jun 2, 2024 09:30AM Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
Jun 2, 2024 09:10AM Hour One Enables Life-Like Cinematic Avatar of NVIDIA CEO Jensen Huang at Computex 2024
Jun 2, 2024 09:00AM Introducing Red Kale Medley, a Mix of Baby Red and Green Kale Complemented by B&W’s Signature Watercress
Jun 2, 2024 09:01AM Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Jun 2, 2024 09:00AM ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
Jun 2, 2024 08:56AM NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
Jun 2, 2024 08:52AM NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
Jun 2, 2024 08:44AM Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
Jun 2, 2024 08:42AM Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 2, 2024 08:41AM NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
Jun 2, 2024 08:35AM Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
Jun 2, 2024 08:32AM NVIDIA Supercharges Ethernet Networking for Generative AI
Jun 2, 2024 08:30AM Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
Jun 2, 2024 08:30AM Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
Jun 2, 2024 08:30AM Vention to democratize industrial automation using NVIDIA AI technologies
Jun 2, 2024 08:30AM Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Jun 2, 2024 08:23AM GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
Jun 2, 2024 08:13AM NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
Jun 2, 2024 08:11AM NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
Jun 2, 2024 08:05AM IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
Jun 2, 2024 08:00AM ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
Jun 2, 2024 08:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
Jun 2, 2024 08:00AM OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
Jun 2, 2024 08:00AM Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
Jun 2, 2024 08:00AM Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Jun 2, 2024 08:00AM Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Jun 2, 2024 08:00AM William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol
Jun 2, 2024 08:00AM CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
Jun 2, 2024 07:00AM RentFinder.ai Sets New Standards in Rental Estimates, Achieves 250% Surge in Usage
Jun 2, 2024 07:00AM Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
Jun 2, 2024 07:00AM June Joy at Juicy Stakes Casino
Jun 2, 2024 07:34AM Accelerate Your Establishment Forward By Implementing These Simple Corporate Hacks
Jun 2, 2024 07:34AM Exploring The Main Aspects To Consider When Eradicating Pesky Pests From Your Home
Jun 2, 2024 06:18AM Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Jun 2, 2024 06:37AM Top 10 Compelling Reasons Why Your Kids Should Have Regular School Physicals
Jun 2, 2024 06:23AM Odyssey Capital participated in the Washington D.C. Blockchain Summit, proposing the establishment of a Global Special Assets Alliance Fund initiative.
Jun 2, 2024 06:15AM Are Ruby Gemstones Worth Investing In?
Jun 2, 2024 04:00AM BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Jun 2, 2024 03:39AM Capsucup: Where Quality and Sustainability Meet in Italian Espresso
Jun 2, 2024 03:23AM Leading Contractor Marketing Agency Webrunner Media Broadens Service Portfolio
Jun 2, 2024 03:21AM Xfive Recognized as a Clutch Global Leader for Spring 2024
Jun 2, 2024 02:00AM ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
Jun 2, 2024 01:13AM Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
Jun 2, 2024 12:57AM Eyes Defined Introduces 3D Images to Revolutionize Eyelid Surgery Planning
View Older Stories